DB-1311 + itraconazole

DB-1311 + itraconazole is a combination drug regimen currently under investigation for the treatment of advanced or metastatic solid tumors. DB-1311 is an investigational antibody-drug conjugate (ADC) that targets the protein B7-H3, which is associated with poor prognosis and drug resistance in cancer[1][3]. DB-1311 consists of an anti-B7-H3 monoclonal antibody linked to P1021, a payload that inhibits DNA replication in cancer cells[1]. Itraconazole is a triazole antifungal agent that is sometimes repurposed for cancer therapy due to its anti-proliferative and anti-angiogenic properties; it also acts as a CYP3A4 inhibitor and P-glycoprotein inhibitor, making it a significant factor in drug-drug interactions during combination regimens. The combination is used in clinical studies, typically to assess safety, tolerability, and pharmacokinetics, and may involve a drug-drug interaction (DDI) cohort to examine the impact of CYP3A/P-gp/OATP1B1 inhibition on DB-1311 metabolism[3].